Chimerix’s (CMRX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Chimerix (NASDAQ:CMRX) in a research note published on Tuesday morning,RTT News reports. Wedbush currently has a $6.00 price objective on the biopharmaceutical company’s stock. Wedbush also issued estimates for Chimerix’s Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.04) EPS.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research report on Monday, November 11th. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st.

Chimerix Stock Performance

Shares of NASDAQ CMRX opened at $2.94 on Tuesday. Chimerix has a 1 year low of $0.75 and a 1 year high of $3.39. The firm has a market cap of $264.41 million, a P/E ratio of -3.13 and a beta of 1.02. The stock has a fifty day moving average price of $1.03 and a two-hundred day moving average price of $0.94.

Hedge Funds Weigh In On Chimerix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in shares of Chimerix in the 2nd quarter worth approximately $137,000. Valeo Financial Advisors LLC raised its holdings in shares of Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 69,505 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 138,098 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.